Ramino-Bio
Oral drug for treating cardio-metabolic disease and rare MSUD
StartupRamino-Bio is a -based startup in the Health Tech & Life Sciences sector, established in 2018. Oral drug for treating cardio-metabolic disease and rare MSUD. Key investors include Johnson & Johnson Innovation, RMGP Biopharma Investment Fund, FutuRx, among 6 total investors. The company has 1-10 employees. Core technologies: Materials & Substances.
The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQ
- Last RoundUndisclosed
- Johnson & Johnson Innovation
- RMGP Biopharma Investment Fund
- FutuRx
6 investors total
What does Ramino-Bio do?
Ramino Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD). Ramino Bio’s unique technology addresses the unmet need of several metabolic diseases in the emerging novel elevated BCAA (Branched-chain amino acid) field. With a druggable lead compound, showing efficacy in-vivo, Ramino Bio is heading preclinical stages. First-in-human studies are planned within 18 months with our lead candidate. We are committed to developing effective therapies for the benefit of the patients.
What sector is Ramino-Bio in?
Ramino-Bio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Materials & Substances. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Ramino-Bio located?
Ramino-Bio is based in Ilan Ramon St 2, Ness Ziyyona, Israel.